Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Katayama

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
European Urology Focus|June 15, 2021
Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-AnalysisEkaterina Laukhtina, Pawel Rajwa, Keiichiro Mori, et al.
BJU International|September 11, 2024
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancerKang Liu, Rossella Nicoletti, Hongda Zhao, et al.
Annals of Surgical Oncology|March 29, 2022
Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical CystectomyKeiichiro Mori, Victor M Schuettfort, Satoshi Katayama, et al.
Molecular Carcinogenesis|September 29, 2021
Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladderEkaterina Laukhtina, Victor M Schuettfort, David D'Andrea, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Urologic Oncology|July 16, 2021
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysisEkaterina Laukhtina, Keiichiro Mori, David D Andrea, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2021
Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaborationKeiichiro Mori, Irene Resch, Noriyoshi Miura, et al.
Clinical Genitourinary Cancer|February 14, 2025
Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisIchiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, et al.
European Urology Focus|August 29, 2021
The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical CystectomyKeiichiro Mori, Victor M Schuettfort, Satoshi Katayama, et al.
European Urology Open Science|May 9, 2022
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter StudyNico C Grossmann, Pawel Rajwa, Fahad Quhal, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
European Urology Focus|June 15, 2021
Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-AnalysisEkaterina Laukhtina, Pawel Rajwa, Keiichiro Mori, et al.
BJU International|September 11, 2024
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancerKang Liu, Rossella Nicoletti, Hongda Zhao, et al.
Annals of Surgical Oncology|March 29, 2022
Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical CystectomyKeiichiro Mori, Victor M Schuettfort, Satoshi Katayama, et al.
Molecular Carcinogenesis|September 29, 2021
Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladderEkaterina Laukhtina, Victor M Schuettfort, David D'Andrea, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Urologic Oncology|July 16, 2021
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysisEkaterina Laukhtina, Keiichiro Mori, David D Andrea, et al.
Cancer Immunology, Immunotherapy : CII|February 16, 2021
Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaborationKeiichiro Mori, Irene Resch, Noriyoshi Miura, et al.
Clinical Genitourinary Cancer|February 14, 2025
Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisIchiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, et al.
European Urology Focus|August 29, 2021
The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical CystectomyKeiichiro Mori, Victor M Schuettfort, Satoshi Katayama, et al.
European Urology Open Science|May 9, 2022
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter StudyNico C Grossmann, Pawel Rajwa, Fahad Quhal, et al.
Pageof 15